Plasminogen Regulates GLP-1 Pathways for Diabetes Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for GLP-1/GLP-1R-related diseases, such as diabetes and obesity, are limited in their ability to effectively regulate GLP-1 and GLP-1 receptor pathways, leading to suboptimal management of these conditions.
Innovation Solution
The use of plasminogen to regulate GLP-1/GLP-1R pathways, either alone or in combination with other drugs or therapies, to treat conditions associated with these pathways, including diabetes, obesity, and neurodegenerative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for GLP-1/GLP-1R-related diseases, then treatment is provided, but the ability to effectively regulate GLP-1 and GLP-1 receptor pathways is limited
Solution Approach 1:
The patent uses plasminogen as an intermediary substance to regulate GLP-1/GLP-1R pathways. Plasminogen acts as a mediator that enhances the activity and efficacy of GLP-1 receptor signaling, thereby improving the reliability of pathway regulation and expanding treatment capabilities for diabetes and related conditions.
2Reliability
If plasminogen is administered to regulate GLP-1/GLP-1R pathways, then GLP-1 expression is promoted and glucagon secretion is inhibited, but the complexity of the treatment regimen increases
Solution Approach 1:
Plasminogen serves multiple functions simultaneously: it promotes GLP-1 expression, inhibits glucagon secretion, and improves glucose tolerance. This multi-functionality allows a single treatment agent to address multiple aspects of diabetes management, thereby improving reliability without proportionally increasing treatment complexity.
Data Source
Figure 1A~4C
Figure 5A~6D
Figure 7~9
AI summary
The present invention discloses the use of plasminogen to regulate GLP-1/GLP-1R and treat a GLP-1/GLP-1R-related condition.